Comprehensive GC–MS/MS Quantification of Gut Microbiota–Derived Metabolites Across Intestinal and Systemic Tissues

The gut microbiota plays a central role in host physiology through the production and transformation of a wide range of bioactive metabolites that influence metabolic, cardiovascular, gastrointestinal, neurological, and oncological processes. To enable robust investigation of these microbiota–host metabolic interactions, a targeted gas chromatography–tandem mass spectrometry (GC–MS/MS) method was developed and validated by a research group at the European Molecular Biology Laboratory (Heidelberg, Germany) for the simultaneous quantification of 120 chemically diverse gut microbiota–derived metabolites across multiple biological matrices. The method employs multiple-reaction monitoring (MRM) in combination with 52 isotopically labeled internal standards, providing high specificity, sensitivity, and quantitative accuracy for key metabolite classes, including short- and branched-chain fatty acids, organic acids, amino acids and their derivatives, indole compounds, and lipid-like molecules. LCGC International recently spoke to Nikita Denisov and Michael Zimmermann, two of the authors of a paper¹ resulting from this work.

Why are gas chromatography–based methods particularly well suited for the analysis of gut microbiota–derived metabolites compared to liquid chromatography-mass spectrometry (LC–MS) or nuclear magnetic resonance (NMR) approaches?

Many microbiota-derived metabolites are small, volatile, and thermally stable, such as short-chain fatty acids, organic acids, and amino acid derivatives. Therefore, gas chromatography (GC)-based methods are particularly well suited for their analysis because these compounds can be efficiently separated in the gas phase after derivatization, providing high chromatographic resolution. This allows reproducible separation of structurally similar molecules (such as five-carbon carboxylic acids - isovaleric acid and valeric acid). Furthermore, GC–MS is less affected by matrix-related ion suppression and offers higher sensitivity for low-abundance microbial products compared to LC-MS and NMR approaches, respectively. Overall, these characteristics make GC-based methods a powerful tool for quantifying relevant gut microbiota-derived metabolites.

What analytical challenges do volatile and low–molecular-weight metabolites such as short-chain fatty acids pose, and how does chemical derivatization address these challenges in GC analysis?

Volatile and low–molecular-weight metabolites such as short-chain fatty acids pose several analytical challenges. These challenges include adequate preanalytical sample handling and preparation, limited interaction with the stationary phase leading to co-elution and peak tailing, and limited collision-induced fragmentation because of small molecular weight. Chemical derivatization addresses these challenges by converting the metabolites into larger, thermally stable, and less polar derivatives, thereby improving chromatographic separation efficiency and collision-induced fragmentation. Furthermore, spiking sodium hydroxide during extraction further minimizes analyte loss by keeping short-chain fatty acids in their deprotonated form, reducing volatilization and preserving them in the sample until derivatization.

Can you explain the rationale for using a targeted GC–tandem mass spectrometry (MS/MS) approach with multiple-reaction monitoring (MRM) rather than an untargeted metabolomics strategy?

A targeted GC–MS/MS approach using MRM is employed to achieve high sensitivity and selectivity, allowing us to apply quantitative analysis for chosen metabolites of interest. MRM allows the selection of specific precursor–product ion transitions, which greatly improves signal-to-noise (S/N) ratio. This results in lower limits of detection and generally higher quantification accuracy compared to untargeted metabolomics approaches.

How does the use of isotopically labeled internal standards improve quantitative accuracy and reproducibility across complex biological matrices like feces, plasma, and the liver?

The use of isotopically labeled internal standards improves quantitative accuracy and reproducibility by compensating for sample preparation losses, altered derivatization efficiency across samples. Furthermore, isotopically labeled internal standards compensate for matrix effects that can vary across complex biological matrices such as intestinal content, feces, plasma, or even stabilization buffers. In our method, we measure the ratio between the isotopically labeled standard and unlabeled analyte, which allows us to correct for variability in extraction, volatilization, and ionization efficiency caused by the matrix.

What criteria are important when developing and validating MRM transitions for a large panel of chemically diverse metabolites?

When developing and validating MRM transitions, it is important to select specific precursor and product ions that are both abundant and unique to each metabolite to minimize interference from co-eluting compounds. Collision energy should be optimized for each transition to maximize signal intensity. Furthermore, chromatographic separation is also essential, especially for structurally similar metabolites, to prevent false peak annotation since the number of MRMs per time is limited. The MRM transitions must be validated for linearity and dynamic range across the expected concentrations in biological samples to ensure accurate quantification.

How does matrix complexity and composition (for example, intestinal contents versus plasma) influence chromatographic separation, ionization efficiency, and quantification in GC–MS/MS?

Matrix complexity and composition have a significant impact on chromatographic separation, ionization efficiency, and quantification by GC–MS/MS. Complex matrices such as intestinal contents contain a variety of salts, proteins, lipids, and other compounds that can potentially interfere with derivatization and chromatographic separation. Matrix components can also influence ionization efficiency, leading to ion suppression or enhancement in the mass spectrometer. Finally, matrix effects can compromise quantification, particularly for low-abundance metabolites, by suppressing their signal and introducing high variability in peak intensity. The spiking of internal standards is thus necessary to ensures accurate and reproducible quantification across complex biological matrices.

What are the implications of using DNA/RNA stabilization buffers on chromatographic performance and mass spectrometric detection, and how was compatibility assessed in this study?

These buffers contain salts, preservatives, or other additives that can interfere with derivatization, alter chromatographic behavior, or suppress ionization in the mass spectrometer, potentially reducing sensitivity and accuracy. To assess the compatibility of our method, we homogenized intestinal contents and divided it into four aliquots across three storage conditions: (i) freshly frozen samples without any added solution, (ii) samples stored in an Invitek stabilization buffer, and (iii) samples stored in an OMNIgene gut stabilization buffer. We observed that metabolite intensities in samples stored in the Invitek buffer were generally lower than those in freshly frozen or OMNIgene-stored samples leading to a reduced limit of detection. However, the extensive use of internal standards could compensate for this loss of signal intensity for most metabolites to still enable their accurate quantification.

Why is normalization to wet tissue weight commonly used in metabolomics studies, and what are its limitations compared to alternative normalization strategies?

Normalization to wet tissue weight is commonly used in metabolomics studies because it provides a straightforward way to account for differences in sample mass, allowing metabolite concentrations to be expressed relative to the amount of biological material analyzed. This approach is simple, reproducible, and applicable across a wide range of sample types, including tissues such as liver, feces, or cecal contents. However, normalization to wet weight has several limitations. First, water content can vary between samples because of hydration status, disease state, or sample handling, which may introduce variability independent of actual metabolite levels. Second, it does not account for differences in cellularity, tissue composition, or extracellular content, which can also affect metabolite concentrations. Third, for highly heterogeneous matrices such as feces or cecal material, wet weight may not reflect the biologically active fraction contributing to metabolism. Alternative normalization strategies, such as normalizing to protein content, DNA content, or metabolite-specific internal standards, can provide a more accurate estimation of the biologically active material and correct for differences in extraction efficiency or sample composition.

How can comparisons between germ-free and conventionally raised animal models help validate the specificity and biological relevance of chromatographic–spectrometric metabolomics methods?

Comparisons between germfree and conventionally raised animal models provide a powerful approach to validate both the specificity and biological relevance of chromatographic–spectrometric metabolomics methods aiming at the quantification of microbiome-dependent metabolites. Germ-free animals lack a microbiota, so metabolites that are exclusively or predominantly produced by gut microbes, such as short-chain fatty acids, certain bile acids, or microbial-derived amino acid derivatives, are expected to be absent or present at low levels only. Detecting these metabolites in conventionally raised animals but not in germ-free animals demonstrates that the method specifically captures microbiota-derived compounds rather than endogenous host metabolites or analytical artifacts.

In the context of microbiome research, how can robust quantitative GC–MS/MS metabolite data complement sequencing-based approaches to improve mechanistic understanding of host–microbiota interactions?

Robust quantitative metabolite data complement sequencing-based microbiome approaches by providing a functional readout of microbial activity rather than just taxonomic composition or functional potential. Although sequencing identifies which microbial taxa or genes are present, it does not reveal whether these microbes are actively producing metabolites or how these compounds affect the host. Furthermore, quantitative metabolite data allows direct comparisons between studies and cohorts and easier translation of in vitro models to in vivo findings. The resulting mechanistic understanding of host–microbiota metabolic interactions hence helps identify functional metabolic links that could be targeted for therapy and prevention. Altogether, we believe that our developed method to quantify gut microbiota-produced metabolites contributes to future microbiome studies aiming at functionally link sequencing data with physiological and mechanistic insights into microbiome-host metabolic interactions.

References

1. Denisov, N.; Springer, F.; Brauer-Nikonow, A. et al. Development of a GC-MS/MS Method to Quantify 120 Gut Microbiota-Derived Metabolites. Anal Bioanal Chem. 2025.DOI: 10.1007/s00216-025-06256-6